Promising combo for cervical cancer hits roadblock: trial ends early
NCT ID NCT00421096
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-free survival. Only 19 people enrolled before the study was terminated, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gemcitabine and cisplatin chemotherapy plus radiotherapy
What this could lead to
If successful, this could point toward a more effective treatment sequence for advanced cervical cancer.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited and may not be reliable. The combination also carries risks like low blood cell counts and organ toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leonard de Vinci
Dechy, 59187, France
-
Centre Oscar Lambret
Lille, 59020, France